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Decreased Retinol Binding Protein 4 Concentrations
are Associated With Cholesterol Gallstone Disease
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Chen-Guo Ker,2 King-Teh Lee2*
Background/Purpose: Circulating retinol binding protein 4 (RBP4) is associated with a variety of obesity-
related diseases. This study investigated whether there were aberrant concentrations of RBP4 in cholesterol
gallstone disease.
Methods: Serum RBP4 levels of 100 cholesterol gallstone patients and 147 healthy controls were mea-
sured by enzyme-linked immunosorbent assay and further correlated with clinical and biochemical char-
acteristics, including insulin resistance and renal function. Gallstone specimens were obtained during
laparoscopic cholecystectomy and analyzed for their chemical composition using Fourier transform in-
frared spectroscopy.
Results: Significantly lower serum RBP4 levels were found in patients with cholesterol gallstones in com-
parison with controls (30.57 ± 13.64 mg/L vs. 41.52 ± 20.25 mg/L, p < 0.001). Lower serum RBP4 levels were
also associated with gallstone occurrence (odds ratio = 0.93; 95% confidence interval = 0.88–0.96; p = 0.004).
Serum RBP4 levels of all subjects were positively correlated with total cholesterol, triglyceride, creatinine,
insulin resistance and albumin, and inversely correlated with aspartate aminotransferase and alanine
aminotransferase. In multivariate analysis, cholesterol gallstone formation was significantly associated
with a lower serum RBP4 level (odds ratio = 4.2; 95% confidence interval = 1.40–12.57; p = 0.010). RBP4
levels were significantly decreased regardless of renal function in patients with gallstones, but levels in-
creased proportionate to renal dysfunction in people without gallstones.
Conclusion: Circulating RBP4 decreases in cholesterol gallstone disease independent of renal function.
Further studies are needed to investigate the relationship between liver function and RBP4 levels in these
patients.
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Since adipose tissue has been recognized as an
endocrine organ, a number of adipokines have
been contiguously reported.1,2 Because adipo-
kines, which are transported via blood flow, have
several effects on human physiology, there is
great interest in their possible metabolic role in 
a variety of obesity-related diseases.3−6 Retinol
binding protein 4 (RBP4), a protein previously
thought to deliver retinol from the liver to pe-
ripheral tissues, has recently been identified by
Yang et al as an adipokine capable of inducing in-
sulin resistance (IR) in liver and skeletal muscle.7
Studies have attempted to clarify the clinical
roles of RBP4 by measuring its circulating con-
centrations in various metabolic disorders, in-
cluding type 2 diabetes, coronary artery disease,
and non-alcoholic fatty liver disease.8−11 Further-
more, increases in circulating RBP4 concentra-
tions have been found in diabetic patients with
chronic renal disease, independent of IR.12,13
Therefore, the possible relationship between IR,
renal function and circulating RBP4 needs further
investigation.
In Western societies, gallstone disease is tradi-
tionally one of the most common and costly of all
digestive diseases.14 Owing to changes in lifestyle,
it has also become common in Taiwan, where over
the past decade there has been an increase in pa-
tients receiving laparoscopic cholecystectomies for
gallstone disease, creating a burden on health care
resources in this country.15−17 Gallstones can be
divided into cholesterol gallstones and pigment
gallstones, based on their dominant chemical
composition. Cholesterol gallstones, which form
from abnormalities of lipid metabolism, have
been strongly associated with obesity,18 IR,19 and
adipokines such as leptin and adiponectin.20,21
However, no study has investigated the possible
association between circulating RBP4 and the 
development of cholesterol gallstones.
Therefore, this study investigated whether ab-
errant levels of circulating RBP4 may be found in
patients with cholesterol gallstone disease. To do
this, we measured serum RBP4 levels in patients
with gallstones and control subjects. We addi-
tionally studied the possible correlation between
circulating RBP4 and other clinical characteristics,
including IR and renal function.
Methods
Subjects
We recruited patients admitted for gallstone disease
at the Department of Surgery of Kaohsiung Med-
ical University Hospital from January to July 2008.
We excluded patients who had a history of liver cir-
rhosis and other concomitant biliary diseases (e.g.
common bile or intrahepatic duct stones). A total
of 164 patients received laparoscopic cholecystec-
tomy and those extracted gallstone specimens were
analyzed for their chemical composition using
Fourier transform infrared spectroscopy. Any gall-
stone with cholesterol content comprising more
than 70% of the dry weight was defined as a choles-
terol gallstone.22 One hundred patients (61.0%),
including 44 men (44.0%) and 56 women
(56.0%), were found to have cholesterol gallstones
and were eligible for this study. Their mean age was
52.78±13.30 years, ranging from 25–78 years, and
mean body mass index (BMI) was 24.44 ± 2.99.
Control subjects were randomly recruited from
people receiving regular medical check-ups at
the Center of Health Examination of Kaohsiung
Medical University Hospital that were confirmed
not to have gallstone diseases via abdominal ultra-
sound. Furthermore, eligible controls were se-
lected stepwise according to age, gender and BMI.
One hundred and forty-seven healthy subjects, in-
cluding 60 men (40.8%) and 87 women (59.2%),
were included in the control group. The average
age was 52.16 ± 7.43 years, ranging from 33–78
years with a mean BMI of 23.75 ± 2.28. The Insti-
tutional Review Board of the Kaohsiung Medical
University Hospital approved the protocol of this
study, and informed consent was obtained from
all patients and controls.
Laboratory analysis
All blood samples were taken between 0800 and
0900 hours, after a 12-hour overnight fast. The
samples were immediately centrifuged and frozen
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at –20oC until further study. Serum levels of total
cholesterol, triglyceride, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), creatinine
(Cr), fasting glucose and albumin were deter-
mined following standard laboratory procedures.
Serum RBP4 concentrations were determined
using an available enzyme-linked immunosorbent
assay system (Immundiagnostik AG, Bensheim,
Germany). Serum insulin concentrations were
measured using a radioimmunoassay system
(Diagnostic Products Corporation, Los Angeles,
CA, USA). All samples were measured in tripli-
cate and the mean of the three measurements
was used in further statistical analyses. The sensi-
tivities of the RBP4 enzyme-linked immuno-
sorbent assay and the insulin RIA were 0.9 μg/L
and 1.2 μU/mL, respectively. Intra-assay and inter-
assay coefficients of variation were 5.0% and 9.5%
for RBP4, and < 10.0% and 7.3% for insulin.
IR index was determined using homeostasis
model assessment (HOMA – IR = fasting insulin
(μU/mL) × fasting glucose (mg/dL) × 0.05551/
22.5). Renal dysfunction was calculated as the
estimated glomerular filtration rate (GFR) using
the Modification of Diet in Renal Disease equation
(MDRD).23 The data are presented as GFR by the
MDRD equation (MDRD-GFR). Renal dysfunction
was defined based on the criteria established by
the National Kidney Foundation.24
Statistical analysis
The data are presented as mean ± standard devia-
tion. Single-variable analyses were performed using
a two-tailed Student’s t test and χ2 test, and con-
firmed by Fisher’s exact test. Multivariable analyses
were performed using a logistic regression model.
Spearman correlation coefficients between RPB4
and other continuous variables were determined
using a bivariate correlation test. In all cases, a 
p value of < 0.05 was considered significant. All
statistical operations were performed using the
statistical package SPSS version 11.0 (SPSS Inc.
Chicago, IL, USA).
Results
The clinical characteristics of all subjects, includ-
ing 100 gallstone patients and 147 controls, are
shown in Table 1. There were no significant dif-
ferences in gender, age, BMI, Cr and IR between
these two groups. The patients with gallstones had
significantly higher waist circumference, total cho-
lesterol, triglyceride, AST, ALT and fasting glucose
Table 1. Clinical characteristics of gallstone patients and control subjects*
Gallstone patients (n = 100) Control subjects (n = 147) p
Gender (M:F) 44:56 60:87 0.694
Age (yr) 52.78 ± 13.30 52.16 ± 7.43 0.674
BMI (kg/m2) 24.44 ± 2.99 23.75 ± 2.28 0.052
WC (cm) 84.75 ± 7.94 79.99 ± 8.62 < 0.001
Cholesterol (mg/dL) 199.03 ± 50.42 181.38 ± 33.81 0.003
Triglycerides (mg/dL) 140.59 ± 81.13 104.01 ± 56.77 < 0.001
AST (IU/L) 34.61 ± 43.15 15.29 ± 5.38 < 0.001
ALT (IU/L) 43.09 ± 47.50 12.76 ± 7.13 < 0.001
Cr (mg/dL) 0.85 ± 0.25 0.82 ± 0.38 0.350
FG (mg/dL) 115.89 ± 45.99 101.97 ± 23.57 0.006
HOMA-IR 0.86 ± 0.79 1.04 ± 0.81 0.250
Albumin (g/dL)† 4.12 ± 0.27 4.34 ± 0.18 < 0.001
RBP4 (mg/L) 30.57 ± 13.64 41.52 ± 20.25 < 0.001
*Data presented as mean ± standard deviation; †undetermined in small cases; 13 in gallstone patients and 20 in control subjects, 
respectively; BMI = body mass index; WC = waist circumference; AST = aspartate aminotransferase; ALT = alanine aminotransferase;
Cr = creatinine; FG = fasting glucose; HOMA-IR = homeostasis model of assessment–insulin resistance; RBP4 = retinol binding protein 4.
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values, but significantly lower values of albumin
when compared with controls. Importantly, they
also had significantly lower serum RBP4 levels
than controls (30.57 ± 13.64 mg/L vs. 41.52 ±
20.25 mg/L, p < 0.001).
Table 2 shows potential risk factors for cho-
lesterol gallstone diseases as determined by mul-
tivariate analysis. We found that the odds ratio
for a 1 mg/dL increase in serum RBP4 levels was
0.93, suggesting that an increase in RBP4 level
decreased risk in our gallstone cases. A decrease
in serum RBP4 levels, therefore, may potentially
increase the risk of cholesterol gallstone disease.
In addition, subjects with increased cholesterol
as well as ALT levels and decreased albumin lev-
els were also found to be at higher risk. We did
not find waist circumference, increased triglyc-
eride, AST levels, and hyperglycemia to be associ-
ated with gallstone disease.
The correlation analyses of serum RBP4 levels
of all subjects with their clinical and biochemical
characteristics are shown in Table 3. Serum RBP4
levels were positively correlated with total cho-
lesterol, triglyceride, Cr, IR and albumin. In con-
trast, we found serum RBP4 levels to inversely
correlate with AST and ALT levels. To further clarify
the association of cholesterol gallstone disease with
RBP4, median RBP4 value (Table 1) of the controls
was used as the cut off value to divide all of the
subjects into high and low groups. We explored
the association of cholesterol gallstones, and the
potential factors listed in Table 3, with lower serum
RBP4 levels using multivariate analysis. We found
that low serum RBP4 was significantly associated
with cholesterol gallstone disease (odds ratio =
2.97; 95% confidence interval = 1.15–7.68; p =
0.010; Table 4).
Table 3. Correlation of serum retinol binding
protein 4 levels from gallstone patients
and control subjects with their clinical
and biochemical characteristics
Serum RBP4 
levels (mg/L)
rs p
Age (yr) 0.105 0.100
BMI (kg/m2) 0.020 0.755
WC 0.079 0.274
Cholesterol (mg/dL) 0.135 0.034
Triglycerides (mg/dL) 0.183 0.004
AST (IU/L) –0.175 0.006
ALT (IU/L) –0.122 0.056
Cr (mg/dL) 0.394 < 0.001
FG (mg/dL) 0.054 0.401
HOMA-IR 0.273 < 0.001
Albumin (g/dL) 0.241 0.001
BMI = Body mass index; WC = waist circumference; AST = aspar-
tate aminotransferase; ALT = alanine aminotransferase; Cr = cre-
atinine; FG = fasting glucose; HOMA-IR = homeostasis model of
assessment–insulin resistance; RBP4 = retinol binding protein 4.
Table 4. Multivariate analysis for the risk of low
retinol binding protein 4 level*
p OR (95% CI)
Cholesterol gallstone 0.025 2.97 (1.15–7.68)
(yes vs. no)
Gender (male vs. female) 0.326 0.70 (0.35–1.42)
Cholesterol (mg/dL) 0.436 0.99 (0.99–1.01)
Triglycerides (mg/dL) 0.463 0.98 (0.99–1.01)
AST (IU/L) 0.711 1.01 (0.98–1.04)
Cr (mg/dL) 0.380 0.63 (0.23–1.76)
HOMA-IR 0.333 0.82 (0.55–1.23)
Albumin (g/dL) 0.849 0.86 (0.18–4.05)
*Low retinol binding protein 4 level was defined by serum retinol
binding protein 4 level less than the mean value (41.52 mg/L) 
of the control group. OR = Odds ratio; CI = confidence interval;
AST = aspartate aminotransferase; Cr = creatinine; HOMA-IR =
homeostasis model of assessment–insulin resistance.
Table 2. Multivariate analysis of potential
characteristics for cholesterol gallstone
disease
p OR (95% CI)
WC (cm) 0.574 0.98 (0.91–1.06)
Cholesterol (mg/dL) 0.001 1.02 (1.01–1.04)
Triglycerides (mg/dL) 0.104 1.01 (0.99–1.02)
AST (IU/L) 0.924 1.01 (0.87–1.16)
ALT (IU/L) 0.011 1.16 (1.03–1.30)
FG (mg/dL) 0.753 0.99 (0.97–1.02)
Albumin (g/dL) 0.001 0.01 (0.01–0.10)
RBP4 (mg/L) 0.004 0.93 (0.88–0.96)
OR=Odds ratio; CI=confidence interval; WC=waist circumference;
AST=aspartate aminotransferase; ALT=alanine aminotransferase;
FG = fasting glucose; RBP4 = retinol binding protein 4.
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We explored the impact of renal function on
serum RBP4 levels in both gallstone patients and
controls by subdividing them into groups where
serum Cr was ≥ 1.0 mg/dL or < 1.0 mg/dL. Patients
with gallstones were found to have significantly
lower serum RBP4 levels than controls in both
subgroups (p=0.012 and 0.045, respectively; Table
5). Using MDRD-GFR data, all subjects were fur-
ther stratified into three stages of chronic kidney
disease (≥ 90, 60–89 and < 60 mL/min/1.73m2).
The figure shows that a lower MDRD-GFR was
associated with greater serum RBP4 level in the
control group. This trend was not, however, noted
in the gallstone patients.
Discussion
In this study, patients with cholesterol gallstones
had significantly lower serum RBP4 levels than
those without, and lower serum RBP4 levels were
associated with gallstone disease. Studying the
impact of renal function in both groups, we found
patients with gallstones to have significantly lower
serum RBP4 levels than controls in both groups
of serum Cr levels. Finally, we did not observe a
proportional increase of serum RBP4 with chronic
kidney disease in the gallstone patients, as was
observed in the controls.
In most studies, cholesterol gallstones are iden-
tified by examining their morphology and cross-
sectional features. Although most gallstones are
cholesterol gallstones, morphology cannot be pre-
cisely used to exclude the possibility of other types
of gallstones, such as brown pigment gallstones.
Therefore, we used Fourier transform infrared spec-
troscopy to quantify the chemical composition of
the gallstones and found cholesterol gallstones
Table 5. Serum retinol binding protein 4 levels in gallstone patients and control subjects categorized by
serum creatinine levels*
Creatinine (mg/dL) Gallstone patients Control subjects p
≥ 1.0 31.61 ± 1.78 43.49 ± 22.19 0.012
< 1.0 30.24 ± 14.23 35.66 ± 11.20 0.045
*Data presented as mean ± standard deviation.
80
60
40
20
0
≥ 90 60–89 <60
MDRD-GFR (mL/min/1.73m2)
Se
ru
m
 R
B
P4
 le
ve
ls
 (
m
g/
L)
Gallstone patients
Control subjects
Figure. Serum retinol binding protein 4 levels from gall-
stone patients and control subjects stratified by stages of
chronic kidney disease. RBP4 = Retinol binding protein 4;
MDRD-GFR=Modification of Diet Renal Disease-glomerular
filtration rate.
to make up 61% of all specimens we collected.
This quantitative method may help make it possi-
ble for studies to better focus on cholesterol gall-
stones. Several factors together have been implicated
in the development of cholesterol gallstones, in-
cluding aging, female gender and obesity.18 In this
study, in which gallstone patients and controls
were age-, gender-, and BMI-matched, serum RBP4
levels were significantly lower in the patients with
gallstones than in controls. In addition, a decrease
in RBP4 levels was found to be an independent
factor for gallstone disease, as determined by mul-
tivariate analysis. This observation implies that
circulating RBP4 might be associated with the
development of cholesterol gallstones.
In one previous large-scale population study,
RBP4 levels were found to be higher in men than
women and were positively associated with waist
circumference, total cholesterol, triglyceride and
RBP4 in cholesterol gallstone disease
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IR.25 In our control group, men had higher levels
of RBP4 than women (45.34 ± 13.88 mg/L vs.
38.88 ± 23.39 mg/L). We also found a correlation
between higher levels of RBP4 and waist circumfer-
ence, total cholesterol and triglyceride in the con-
trol group. Another recent study has reported age to
contribute to increases in circulating RBP4 and
influence its association with IR.26 We also found
a positive correlation between serum RBP4 levels
and age in controls, with an especially significant
correlation between serum RBP4 levels and IR in
the younger subjects (25–50 years, rs = 0.310, p =
0.046, data not shown). Serum RBP4 levels were
also found to be significantly correlated with waist
circumference, total cholesterol, triglyceride, and
IR in our gallstone patients. Although we did not
find a significant correlation between serum RBP4
levels and age in these gallstone patients in general,
the serum RBP4 levels in elderly patients (60–78
years) were indeed higher (31.20 ± 12.66 mg/L)
than the young patients (25–50 years; 29.22 ±
14.29 mg/L; data not shown), which has also been
observed previously.26 In addition, in our study,
gallstone patients and controls were matched for
IR (Table 1), suggesting that the reduced RBP4 lev-
els we found in the patients with gallstones oc-
curred independently of IR.
Because RBP4 is normally filtered through the
glomerular basement membrane and reabsorbed
by the renal tubular system, both excessive tubu-
lar capacity and tubular dysfunction could alter
RBP4 homeostasis.27 As has been previously re-
ported,12,13,28 we found a positive correlation be-
tween serum RBP4 levels and serum Cr levels in
the controls. Serum RBP4 levels were significantly
higher in the Cr ≥ 1.0 mg/dL group than in the 
Cr < 1.0 mg/dL (p = 0.042, data not shown). The
mean RBP4 levels increased proportionate to wors-
ening renal filtration function in the controls
(Figure). We did not find this relationship in the
gallstone patients. In fact, patients with gallstones
had significantly lower serum RBP4 levels than the
controls even when both groups were subdivided
into groups with Cr ≥ or < 1.0 mg/dL (Table 5).
Furthermore, unlike in the controls, the change
of average RBP4 levels did not obviously parallel
the MDRD-GFR status in patients with gallstones
(Figure). Taken together, these findings suggest
that renal function does not influence circulating
RBP4 in patients with gallstones.
Because the liver is known to be the major
source of RBP4, some authors have shown great in-
terest in the relationship between liver function
and circulating RBP4 concentrations.29,30 Most re-
cently, Tacke et al stated that liver function criti-
cally determines serum RBP4 levels in patients
with chronic liver disease and cirrhosis.31 Our
study did not find a significant association be-
tween serum RBP4 levels and AST and ALT levels,
as seen in healthy controls, in patients with gall-
stones. Based on supplemental data from a limited
number of blood samples (82 from gallstone pa-
tients and 127 from healthy controls), we found a
significant correlation between serum RBP4 levels
and albumin. Serum albumin levels were signifi-
cantly lower in the gallstone patients than the con-
trols. Thus it may be logical to expect that abnormal
liver function accompanying the formation of cho-
lesterol gallstones might lead to decreased RBP4
levels in gallstone patients.
RBP4, a newly-established adipokine, has been
demonstrated to be associated with several obesity-
related diseases. Moreover, obesity has been con-
sidered to be one of the major risk factors for
cholesterol gallstone disease. In this context, it is
rational to hypothesize the existence of aberrant
circulating RBP4 in patients with cholesterol
gallstones. Indeed, the present study, in which sex,
age and BMI were matched in both the patient and
control groups, showed significant decrease of
serum RBP4 levels in gallstone patients. Although
this cross-sectional study could not specify their
causal relationship, the possible mechanisms that
lead to the decrease in circulating RBP4 in patients
may reveal this adipokine to be a potential bio-
marker in cholesterol gallstone formation. IR and
poor renal function, which have been considered
to be associated with RBP4 concentrations in sev-
eral metabolic disorders,7,12 were excluded to cause
decreased RBP4 concentrations in gallstone disease
in this study. Recent studies have uncovered several
mechanisms related to cholesterol metabolism and
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bile formation. These mechanism occur between
the liver and blood flow, and are considered to
be involved in cholesterol gallstone formation.18,32
Moreover, the liver is the major source of circulat-
ing RBP4. The potential role of cholesterol me-
tabolism and its association with circulating RBP4
levels and gallstone formation within the liver
warrants further investigation.
In conclusion, we found a clear association be-
tween serum RBP4 levels and cholesterol gallstones
independent of IR and renal function. The possi-
bility that this decrease in RBP4 levels in patients
with cholesterol gallstones may result from abnor-
mal liver function requires further investigation.
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